Etanercept biosimilar - Nanogen Biopharmaceutical

Drug Profile

Etanercept biosimilar - Nanogen Biopharmaceutical

Alternative Names: Nanercept

Latest Information Update: 17 Mar 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Nanogen Biopharmaceutical Co
  • Class Antirheumatics; Disease-modifying antirheumatics; Recombinant fusion proteins
  • Mechanism of Action Tumour necrosis factor inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preregistration Psoriasis; Rheumatoid arthritis

Most Recent Events

  • 17 Mar 2016 Etanercept biosimilar is still under preregistration for Rheumatoid arthritis and Psoriasis in Vietnam (SC)
  • 15 Mar 2016 Biomarkers information updated
  • 12 Mar 2014 Preregistration for Psoriasis in Vietnam (SC)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top